CV38-142

N/A

Report date: 2023/11/10 16:45:12

Base Information

Drug NameCV38-142
Drug Alias NameCV38-142
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-Coronavirus spike glycoprotein
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGerman Center For Neurodegenerative Diseases (Dzne)Miltenyi Biotec BV & Co KGHelmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab) +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesLabor Berlin-Charité Vivantes GmbHLabor Dr. Krause & Kollegen MVZ GmbHHelmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab) +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A